Cargando…

Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner

HER2-positive breast cancer (BC) invasiveness and drug-resistance issue is the critical treatment obstacle recently. We investigated the total and phosphorylated status EZH2 expression in database and BC tissue microarray. We demonstrated for the first time that EZH2 is distributed both in cytoplasm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Feng, Li, Lili, Zhang, Mengwen, Sun, Shanshan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557267/ https://www.ncbi.nlm.nih.gov/pubmed/37803297 http://dx.doi.org/10.1186/s12885-023-11450-9

Ejemplares similares

Correction: Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner
por: Yu, Feng, et al.
Publicado: (2023)

CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
por: Nie, Lei, et al.
Publicado: (2019)

Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
por: Nie, Lei, et al.
Publicado: (2020)

EZH2 expression in invasive lobular carcinoma of the breast
por: Roh, SiGyun, et al.
Publicado: (2013)

PYK2 promotes HER2-positive breast cancer invasion
por: Al-Juboori, Shaymaa IK., et al.
Publicado: (2019)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
por: Bao, Yi, et al.
Publicado: (2020)

Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
por: Burguin, Anna, et al.
Publicado: (2020)

Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
por: Kang, Byeongju, et al.
Publicado: (2023)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

SOX5 promotes breast cancer proliferation and invasion by transactivation of EZH2
por: Sun, Chuntao, et al.
Publicado: (2019)

COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer
por: Glynn, Sharon A, et al.
Publicado: (2010)

Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
Publicado: (2020)

EZH2/H3K27Me3 and phosphorylated EZH2 predict chemotherapy response and prognosis in ovarian cancer
por: Sun, Si, et al.
Publicado: (2020)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2
por: Wu, Yifen, et al.
Publicado: (2015)

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis
por: Chen, Shanshan, et al.
Publicado: (2019)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis
por: Anwar, Talha, et al.
Publicado: (2018)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
por: Lewis, Gary. D., et al.
Publicado: (2021)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells
por: Mu, Zhaomei, et al.
Publicado: (2013)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma
por: Pattanayak, Birlipta, et al.
Publicado: (2020)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
por: Kurihara, Hiroaki, et al.
Publicado: (2015)

Phosphorylation of Ser(78 )of Hsp27 correlated with HER-2/neu status and lymph node positivity in breast cancer
por: Zhang, Daohai, et al.
Publicado: (2007)

Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
por: Chen, Wei, et al.
Publicado: (2017)

HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
por: Gijsen, Merel, et al.
Publicado: (2010)

Employing multiplex immunofluorescence to quantify Her2 and phosphorylated Her2 in formalin-fixed, paraffin-embedded breast tumor specimens
por: Donovan, MJ, et al.
Publicado: (2009)

EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features
por: Guo, Shuangping, et al.
Publicado: (2016)

NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer
por: Yuan, Yuan, et al.
Publicado: (2021)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
por: Hong, Joohyun, et al.
Publicado: (2022)

Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy
por: Chen, Wei, et al.
Publicado: (2023)

EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression
por: Gonzalez, Maria E., et al.
Publicado: (2022)

Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
por: Honkanen, Tiia J., et al.
Publicado: (2021)

UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells
por: Hua, Jun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_omdsut59vhk0sqgscd5r7pp0bc